Intranasal esketamine for depression: Not so special K
Sign Up to like & getrecommendations! Published in 2022 at "Australasian Psychiatry"
DOI: 10.1177/10398562221093870
Abstract: Background Intranasal esketamine has been recently approved for the treatment of resistant depression. It is the only form of ketamine approved. The formulation costs around $600 per dose while plain injected ketamine, on which most… read more here.
Keywords: depression special; intranasal esketamine; esketamine; esketamine depression ... See more keywords